Clinical trial
Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer
NCT00212069 · National University Hospital, Singapore, Other · Completed
Key facts
| NCT number | NCT00212069 |
|---|---|
| Title | Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer |
| Official title | Serum Protein Profiling as a Predictor of Gemcitabine Sensitivity in Breast Cancer With Prior Exposure to Anthracyclines and Taxanes |
| Lead sponsor | National University Hospital, Singapore, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, carboplatin |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2013 |
| Completion | Apr 1, 2013 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 11, 2013 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: